The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

(THE CONVERSATION) The Food and Drug Administration’s decision, made public on Feb. 10, 2026, to not review an application to approve Moderna’s proposed mRNA-based flu vaccine set off a firestorm of ...

The FDA has accepted Moderna’s revised approach seeking full approval for the shot for adults aged between 50 and 64, and accelerated approval for those aged 65 and above, the company said, adding ...

RFK Jr.'s attacks on vaccines go beyond changing the childhood immunization schedule. Now he's taking aim at vaccine R&D ...

The Food and Drug Administration will consider whether to approve Moderna’s new flu vaccine after all, resolving a dispute ...

The Food and Drug Administration has reversed course and agreed to review Moderna’s application for the first mRNA-based flu ...

The Food and Drug Administration (FDA) has backtracked its initial decision last week of refusing to review Moderna’s mRNA ...

Moderna's mRNA-1010 flu vaccine for older adults could be made available by the end of 2026, the pharmaceutical company announced on Friday.

The stock’s movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license ...

After initially rejecting Moderna’s application for review, the FDA will now consider the company’s mRNA flu shot ...

Last week, Moderna said that the initial refusal from the FDA was inconsistent with previous feedback from the agency.